Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ADCK2-DPP6

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ADCK2-DPP6
	FusionPDB ID: 2192
	FusionGDB2.0 ID: 2192
		Hgene	Tgene
	Gene symbol	ADCK2	DPP6
	Gene ID	90956	1804
	Gene name	aarF domain containing kinase 2	dipeptidyl peptidase like 6
	Synonyms	AARF	DPL1\|DPPX\|MRD33\|VF2
	Cytomap	7q34	7q36.2
	Type of gene	protein-coding	protein-coding
	Description	uncharacterized aarF domain-containing protein kinase 2putative ubiquinone biosynthesis protein AarF	dipeptidyl aminopeptidase-like protein 6DPP VIdipeptidyl aminopeptidase IV-related proteindipeptidyl peptidase IV-related proteindipeptidyl peptidase VIdipeptidyl-peptidase 6
	Modification date	20200313	20200313
	UniProtAcc	Q7Z695 Main function of 5'-partner protein: FUNCTION: The function of this protein is not yet clear. It is not known if it has protein kinase activity and what type of substrate it would phosphorylate (Ser, Thr or Tyr).	P42658 Main function of 5'-partner protein: FUNCTION: Promotes cell surface expression of the potassium channel KCND2 (PubMed:15454437, PubMed:19441798). Modulates the activity and gating characteristics of the potassium channel KCND2 (PubMed:18364354). Has no dipeptidyl aminopeptidase activity (PubMed:8103397, PubMed:15476821). {ECO:0000269\|PubMed:15454437, ECO:0000269\|PubMed:18364354, ECO:0000269\|PubMed:8103397, ECO:0000305\|PubMed:15476821}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000072869, ENST00000476491,	ENST00000332007, ENST00000377770, ENST00000406326, ENST00000427557, ENST00000496611, ENST00000404039,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	3 X 3 X 3=27	17 X 17 X 7=2023
	# samples	3	19
	** MAII score	log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(19/2023*10)=-3.41242499622733 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ADCK2 [Title/Abstract] AND DPP6 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ADCK2 [Title/Abstract] AND DPP6 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ADCK2(140390613)-DPP6(154429531), # samples:3
Anticipated loss of major functional domain due to fusion event.	ADCK2-DPP6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ADCK2-DPP6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	DPP6	GO:1901379	regulation of potassium ion transmembrane transport	18364354

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:140390613/chr7:154429531)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ADCK2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across DPP6 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000072869

ADCK2

chr7

140390613

ENST00000404039

DPP6

chr7

154429531

5694

1918

178

3888

1236

ENST00000476491

ADCK2

chr7

140390613

ENST00000404039

DPP6

chr7

154429531

5694

1918

178

3888

1236

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000072869	ENST00000404039	ADCK2	chr7	140390613	+	DPP6	chr7	154429531	+	0.000911342	0.99908864
ENST00000476491	ENST00000404039	ADCK2	chr7	140390613	+	DPP6	chr7	154429531	+	0.000911342	0.99908864

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ADCK2-DPP6

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ADCK2	chr7	140390613	DPP6	chr7	154429531	1918	580	LLSSVFKLLMTHKIYQHSYTGYYVLS

Top

Potential FusionNeoAntigen Information of ADCK2-DPP6 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ADCK2-DPP6_140390613_154429531.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:03	HKIYQHSY	0.9571	0.5504	11	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:01	KLLMTHKIY	0.9729	0.7162	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:25	KLLMTHKIY	0.9498	0.6852	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:03	THKIYQHSY	0.5421	0.5646	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:18	THKIYQHSY	0.4995	0.5029	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B38:02	THKIYQHSY	0.2609	0.8276	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:01	THKIYQHSY	0.1441	0.8365	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B52:01	FKLLMTHKI	0.0047	0.7687	5	14
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:01	KIYQHSYTGY	0.9998	0.6593	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B57:01	MTHKIYQHSY	0.9995	0.8171	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:25	KIYQHSYTGY	0.9977	0.6175	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:17	MTHKIYQHSY	0.9963	0.6138	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:17	KIYQHSYTGY	0.9922	0.5738	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-A32:13	KIYQHSYTGY	0.797	0.7171	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:01	KIYQHSYTGYY	0.9998	0.6377	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:25	KIYQHSYTGYY	0.9987	0.5634	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-A32:13	KIYQHSYTGYY	0.9563	0.7014	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:95	THKIYQHSY	0.8906	0.5148	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:27	THKIYQHSY	0.8473	0.8724	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:05	THKIYQHSY	0.7783	0.8835	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:46	THKIYQHSY	0.7305	0.6654	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:80	THKIYQHSY	0.7283	0.8406	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:67	THKIYQHSY	0.7283	0.8406	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:10	THKIYQHSY	0.7244	0.9045	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:21	THKIYQHSY	0.6749	0.776	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:05	KLLMTHKIY	0.6748	0.6108	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:04	KLLMTHKIY	0.6416	0.7076	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B39:12	THKIYQHSY	0.2688	0.6629	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C12:16	THKIYQHSY	0.169	0.9051	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:04	KIYQHSYTGY	0.9961	0.6709	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:05	KIYQHSYTGY	0.979	0.5364	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:04	KIYQHSYTGYY	0.9964	0.6543	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:54	HKIYQHSY	0.9018	0.7279	11	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B48:02	HKIYQHSY	0.8948	0.7422	11	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:27	KLLMTHKIY	0.9745	0.7357	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:33	KLLMTHKIY	0.9729	0.7162	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:34	KLLMTHKIY	0.9729	0.7162	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:125	KLLMTHKIY	0.9729	0.7162	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:135	KLLMTHKIY	0.9726	0.715	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:50	KLLMTHKIY	0.9637	0.7559	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:39	KLLMTHKIY	0.9522	0.5267	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:35	KLLMTHKIY	0.9432	0.6754	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:22	THKIYQHSY	0.8383	0.5409	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:17	THKIYQHSY	0.8064	0.9211	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-C07:02	THKIYQHSY	0.7283	0.8406	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:20	KLLMTHKIY	0.7001	0.6948	6	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B35:20	THKIYQHSY	0.6236	0.7888	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:11	THKIYQHSY	0.4834	0.7871	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B48:02	THKIYQHSY	0.447	0.7609	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:04	THKIYQHSY	0.3378	0.8533	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:53	THKIYQHSY	0.2221	0.7673	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:03	THKIYQHSY	0.2007	0.8219	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:06	THKIYQHSY	0.1768	0.8231	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:07	THKIYQHSY	0.1626	0.7376	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:08	THKIYQHSY	0.1491	0.6159	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B18:05	THKIYQHSY	0.1441	0.8365	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:54	THKIYQHSY	0.1351	0.7487	10	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:135	KIYQHSYTGY	0.9998	0.6651	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:125	KIYQHSYTGY	0.9998	0.6593	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:27	KIYQHSYTGY	0.9998	0.7065	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:34	KIYQHSYTGY	0.9998	0.6593	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:33	KIYQHSYTGY	0.9998	0.6593	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:50	KIYQHSYTGY	0.9998	0.7283	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B57:10	MTHKIYQHSY	0.9995	0.8171	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:35	KIYQHSYTGY	0.9994	0.599	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B57:04	MTHKIYQHSY	0.9993	0.5126	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:12	KIYQHSYTGY	0.9992	0.5915	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:11	MTHKIYQHSY	0.9973	0.7065	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:08	MTHKIYQHSY	0.9969	0.7059	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:20	KIYQHSYTGY	0.9802	0.6234	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-A25:01	MTHKIYQHSY	0.938	0.7056	9	19
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-A32:01	KIYQHSYTGY	0.9278	0.7094	12	22
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:33	KIYQHSYTGYY	0.9998	0.6377	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:27	KIYQHSYTGYY	0.9998	0.679	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:34	KIYQHSYTGYY	0.9998	0.6377	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:125	KIYQHSYTGYY	0.9998	0.6377	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:135	KIYQHSYTGYY	0.9998	0.6432	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:50	KIYQHSYTGYY	0.9998	0.7233	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-B15:35	KIYQHSYTGYY	0.9995	0.5851	12	23
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	HLA-A32:01	KIYQHSYTGYY	0.9902	0.7318	12	23

Top

Potential FusionNeoAntigen Information of ADCK2-DPP6 in HLA II

ADCK2-DPP6_140390613_154429531.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0101	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0101	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0103	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0103	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0103	SVFKLLMTHKIYQHS	3	18
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0103	LLSSVFKLLMTHKIY	0	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0105	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0105	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0107	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0107	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0109	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0109	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0111	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0111	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0113	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0115	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0115	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0117	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0117	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0119	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0119	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0121	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0125	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0125	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0127	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0127	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0129	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0129	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0131	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0131	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0807	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0819	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0819	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0825	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0825	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0832	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0834	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-0834	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1172	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1216	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1216	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1216	LLSSVFKLLMTHKIY	0	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1216	SVFKLLMTHKIYQHS	3	18
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1222	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1222	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1222	LLSSVFKLLMTHKIY	0	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1446	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1515	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1527	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1527	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1531	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1534	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1601	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1601	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1602	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1602	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1603	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1603	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1604	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1604	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1605	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1605	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1607	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1607	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1608	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1608	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1609	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1609	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1610	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1610	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1610	LLSSVFKLLMTHKIY	0	15
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1611	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1611	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1612	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1612	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1614	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1614	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1616	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB1-1616	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB5-0102	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB5-0102	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB5-0103	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB5-0103	LSSVFKLLMTHKIYQ	1	16
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB5-0108N	SSVFKLLMTHKIYQH	2	17
ADCK2-DPP6	chr7	140390613	chr7	154429531	1918	DRB5-0108N	LSSVFKLLMTHKIYQ	1	16

Top

Fusion breakpoint peptide structures of ADCK2-DPP6

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
4395	KLLMTHKIYQHSYT	ADCK2	DPP6	chr7	140390613	chr7	154429531	1918

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ADCK2-DPP6

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	4395	KLLMTHKIYQHSYT	-8.10239	-9.13889
HLA-B14:02	3BVN	4395	KLLMTHKIYQHSYT	-7.95042	-8.06502
HLA-B52:01	3W39	4395	KLLMTHKIYQHSYT	-7.16801	-7.28261
HLA-B52:01	3W39	4395	KLLMTHKIYQHSYT	-6.4432	-7.4797
HLA-A11:01	4UQ2	4395	KLLMTHKIYQHSYT	-8.22003	-8.33463
HLA-A11:01	4UQ2	4395	KLLMTHKIYQHSYT	10001	10000
HLA-A24:02	5HGA	4395	KLLMTHKIYQHSYT	-6.48286	-6.59746
HLA-A24:02	5HGA	4395	KLLMTHKIYQHSYT	-4.84504	-5.88154
HLA-B27:03	6PZ5	4395	KLLMTHKIYQHSYT	-3.7623	-3.8769
HLA-B44:05	3DX8	4395	KLLMTHKIYQHSYT	-6.26312	-6.37772
HLA-B44:05	3DX8	4395	KLLMTHKIYQHSYT	-5.69895	-6.73545
HLA-A02:01	6TDR	4395	KLLMTHKIYQHSYT	-4.06543	-4.18003

Top

Vaccine Design for the FusionNeoAntigens of ADCK2-DPP6

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ADCK2-DPP6	chr7	140390613	chr7	154429531	10	19	THKIYQHSY	ACTCACAAGATATATCAACACTCGTAT
ADCK2-DPP6	chr7	140390613	chr7	154429531	11	19	HKIYQHSY	CACAAGATATATCAACACTCGTAT
ADCK2-DPP6	chr7	140390613	chr7	154429531	12	22	KIYQHSYTGY	AAGATATATCAACACTCGTATACTGGATAT
ADCK2-DPP6	chr7	140390613	chr7	154429531	12	23	KIYQHSYTGYY	AAGATATATCAACACTCGTATACTGGATATTAC
ADCK2-DPP6	chr7	140390613	chr7	154429531	5	14	FKLLMTHKI	TTTAAGTTGCTGATGACTCACAAGATA
ADCK2-DPP6	chr7	140390613	chr7	154429531	6	15	KLLMTHKIY	AAGTTGCTGATGACTCACAAGATATAT
ADCK2-DPP6	chr7	140390613	chr7	154429531	9	19	MTHKIYQHSY	ATGACTCACAAGATATATCAACACTCGTAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ADCK2-DPP6	chr7	140390613	chr7	154429531	0	15	LLSSVFKLLMTHKIY	CTTCTCTCTAGTGTCTTTAAGTTGCTGATGACTCACAAGATATAT
ADCK2-DPP6	chr7	140390613	chr7	154429531	1	16	LSSVFKLLMTHKIYQ	CTCTCTAGTGTCTTTAAGTTGCTGATGACTCACAAGATATATCAA
ADCK2-DPP6	chr7	140390613	chr7	154429531	2	17	SSVFKLLMTHKIYQH	TCTAGTGTCTTTAAGTTGCTGATGACTCACAAGATATATCAACAC
ADCK2-DPP6	chr7	140390613	chr7	154429531	3	18	SVFKLLMTHKIYQHS	AGTGTCTTTAAGTTGCTGATGACTCACAAGATATATCAACACTCG

Top

Information of the samples that have these potential fusion neoantigens of ADCK2-DPP6

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	ADCK2-DPP6	chr7	140390613	ENST00000072869	chr7	154429531	ENST00000404039	TCGA-A8-A07I-01A

Top

Potential target of CAR-T therapy development for ADCK2-DPP6

Predicted 3D structure. We used RoseTTAFold.

13_ADCK2-DPP6_t000_.e2e.pdb

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

ADCK2

chr7:140390613

chr7:154429531

ENST00000072869

103_123

580

627.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene	Hchr	Hbp	Henst	Tgene	Tchr	Tbp	Tenst	DeepLoc result
ADCK2	chr7	140390613	ENST00000072869	DPP6	chr7	154429531	ENST00000404039

Top

Related Drugs to ADCK2-DPP6

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ADCK2-DPP6

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)